Noopur Raje
Massachusetts General Hospital · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Noopur Raje as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06832865 · ELISA in Relapsed/Refractory MMMassachusetts General Hospital · recruiting · Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma · principal investigator
- Ph2NCT06138275 · Elranatamab in R/R Multiple MyelomaMassachusetts General Hospital · recruiting · Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma · principal investigator
- Ph1NCT02886065 · A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMMassachusetts General Hospital · active not recruiting · Smoldering Multiple Myeloma · principal investigator
- Ph1NCT01718899 · Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple MyelomaOncoPep, Inc. · completed · Smoldering Multiple Myeloma · principal investigator
- Ph1NCT00729638 · RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaMassachusetts General Hospital · completed · Multiple Myeloma · principal investigator
- Ph2NCT00577642 · Bone Marker Assessment of Multiple Myeloma Patients Treated With AminobisphosphonatesMassachusetts General Hospital · completed · Multiple Myeloma · principal investigator
- Ph1NCT00547404 · Phase I Study for Safety and Efficacy of P276-00 in Subjects With MyelomaPiramal Enterprises Limited · withdrawn · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:17 UTC. The ranking covers the 200 most relevant of 64 PubMed records, and a shared surname and initials can bring in a namesake. All 64 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- 1,433 citationsRCR 50.4
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9
- 736 citationsRCR 15.1
- 730 citationsRCR 17.8
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Nat Med · 2023617 citationsRCR 54.5
- 433 citationsRCR 32.2
- 358 citationsRCR 14.6
- 337 citationsRCR 19.3
- 324 citationsRCR 9.7